A Precision Webinar

Driving Successful Therapeutic and Diagnostic Development: Effective Practices for Integrating Biomarkers, Biospecimens, and Science from Concept through Clinic to Cloud

In the rapidly evolving world of precision medicine, the successful integration of high-quality biospecimens and well-defined biomarkers is a fundamental aspect. Together with robust scientific methodologies and validation procedures, they drive discovery, clinical development, and the advent of Artificial Intelligence (AI)-driven diagnostics.

This webinar delves into the practical application of biospecimens in critical areas like neurodegeneration, immuno-oncology, and oncology. It outlines the development of assays for clinical application, the creation of multiplexed Immunohistochemistry (IHC) assays, and the use of sequenced biospecimens in the development and diagnosis of targeted therapies.

Key topics will also highlight the value of Tissue Microarrays (TMAs), the advantage of accessing diverse disease indications, the necessity for substantial tissue cohorts for clinical trial assay validation, and the role of tissue images (Hematoxylin & Eosin (H&E), IHC) and related sample data (Next-Generation Sequencing (NGS)) in shaping AI-based diagnostics.

By attending this webinar, participants can expect to:

• Gain insights into best practices for successful biomarker discovery and clinical application.
  
• Understand the pivotal role of high-quality biological specimens in therapeutic development.
• Delve into case studies that demonstrate the successful realization of these strategies across a variety of therapeutic areas.
• Comprehend the current trends and future potential of AI-driven diagnostics in the field of precision medicine.

Amanda Woodrooffe, Ph.D.

Senior Vice President, General Manager UK Labs

Dr. Woodrooffe brings years of experience as a leader of scientific operations both with pharmaceutical companies and with contract research organizations, so she’s directly familiar with both sides of the table and excels as a collaborative partner. She focuses on methods and approaches to provide actionable data which can directly enable biopharmaceutical research and development. She earned her PhD, focused on drug metabolism, from the University of Cambridge.

Robert Snyder, Ph.D.

Associate Director, Genomics

Dr. Snyder has a 20-year track record in genomics, with a focus on in vitro diagnostic assay development and bioinformatics.
His journey has equipped him with regulatory expertise for V&V study designs, a grasp of orthogonal methods, and an appreciation for biospecimens in transitions from benchtop to bedside. His collaborative nature leads to actionable data for biomedical development. Dr. Snyder holds a PhD from the joint Department of Biomedical Engineering at North Carolina State University and the UNC Chapel Hill School of Medicine.